A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung.

Tsurumi, Kyoji; Kawashima, Yosuke; Akahira, Junichi; Saito, Ryohei; Toi, Yukihiro; Nakamura, Atsushi; Yamanda, Shinsuke; Kimura, Yuichiro; Honda, Yoshihiro; Sugawara, Shunichi

Tsurumi, Kyoji; Kawashima, Yosuke; Akahira, Junichi; Saito, Ryohei; Toi, Yukihiro; Nakamura, Atsushi; Yamanda, Shinsuke; Kimura, Yuichiro; Honda, Yoshihiro; Sugawara, Shunichi.

Afiliação

Tsurumi K; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kawashima Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Akahira J; Department of Pathology, Sendai Kousei Hospital, Sendai, Japan.
Saito R; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Toi Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Nakamura A; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Yamanda S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kimura Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Honda Y; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.

JMA J ; 3(1): 83-86, 2020 Jan 15.

Article em En | MEDLINE | ID: mdl-33324781

Palavras-chave

PD-L1; Pembrolizumab; Sarcomatoid carcinoma; Spindle cell carcinoma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: JMA J Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google